Fig. 2
Effect of mTOR overexpression and Evr treatment on GEMsen and GEMres cell migration. a Transwell assay of the migration of GEMsen and GEMres cells with or without ov-mTOR transfection or/and Evr treatment after 48 h of incubation. Scale bar, 100 μm. b Quantification of the number of migrating GEMsen and GEMres cells. The numbers in the arrows represent the difference (increase or decrease) in cell count between ov-mTOR and ov-mTOR + Evr. In ov-mTOR-transfected GEMres cells, the suppressive effect of Evr on migration ability was stronger than that in ov-mTOR-transfected GEMsen cells. c Ratio of the number of migrated GEMres cells to that of migrated GEMsen cells. The data are expressed as the mean ± standard deviation of three replicates (n = 3). *P < 0.05; #P < 0.05 compared with the same treatment in GEMsen cells. GEM: gemcitabine, Evr: everolimus; GEMsen: GEM-sensitive pancreatic cancer cells; GEMres: GEM-resistant pancreatic cancer cells